Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Oatly Group AB - ADR — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Oatly Group AB - ADR trades at $11.1 (market cap $347.84M). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 25.5× Oatly Group AB - ADR's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Oatly Group AB - ADR for 18 Days on average.
| KYMR | OTLY | |
|---|---|---|
Market Cap | $8.87B | $347.84M |
Volume | 779,107 | 116,933 |
Sector | Health | Consumer Staples |
52-Week High | $127.31 | $15.91 |
52-Week Low | $55.80 | $8.03 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $8.26B | $852.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OTLY trades at $11.15, up 4.5% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $862M in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Recent Q2 2026 results beat expectations and management raised full-year revenue guidance, driving positive sentiment.
While OTLY demonstrates operational progress with margin improvement and revenue acceleration, significant risks remain including persistent losses, high debt levels, and negative cash flow. Analyst consensus is mixed with 44% buy ratings but a modest $12.28 price target suggesting limited upside from current levels amid ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
